Chris Jensen

UNC Hematology/Oncology. Malignant hematology + Geriatric oncology.

[Chris Jensen @ChrisJensenMD]

Excited to present our updated AML home time data to a new audience at #ARM23!

[Deborah Stephens @DebbieMStephens]

Congrats to all, but special shout out to @ChrisJensenMD for his work to address fatigue for patients with #CLL. @UNC_Lineberger @UNC_Health_Care

[Cancer and Aging Research Group (CARG) #GeriOnc @myCARG]

Which leads us to the all-important question…“Why Is #GeriatricAssessments so Infrequently Used in Oncology Practices? The Ongoing Issue of Nonadherence to This Standard of Care for #OlderAdults With #Cancer” https://t.co/xaalIVqiY9 #PracticalGA23 #OncoAlert #OlderAdults 13/13

[William Dale, MD, PhD, FASCO @WilliamDale_MD]

The new #GeriOnc Guidelines from #ASCO are out!!
Very proud to lead the esteemed group of researchers, clinicians, patient partners, nurses, and so many others to make this a reality.

More to come! Follow https://t.co/l1x8DGCrDT for more updates.

https://t.co/5GXnUbsMbn

[Christine A. Garcia, MD, MPH @christinemphmd]

Excitied to share new guidelines, tools, infographics & VIDEO from @ASCO Older Adult Taskforce on #GeriatricAssessment & management of #olderadults with cancer!

Guidelines in @JCO_ASCO
https://t.co/fQezZVLxsL…
Video on GA: https://t.co/CYqAF2FFOx

[Chris Jensen @ChrisJensenMD]

@RahulBanerjeeMD I see CLL and lymphoma clinically, though our Geri-onc and supportive care work has been in heme malignancy more broadly!

[Chris Jensen @ChrisJensenMD]

Excited to present our work on supporting older adults undergoing treatment for myeloma @ #ASCO23 this afternoon. #GeriOnc #mmsm. https://t.co/XRE7x9E0cZ

[calliecoombs @calliecoombsmd]

Glad to see this out in NEJM - demonstrating clear superiority of obin over ritux in frontline CLL, with minimal benefit from addition of ibrut (IVO) but with significant increase in infections https://t.co/4CE8Z0ejL2

[Lorinda A. Coombs, PhD, FNP-BC, AOCNP @LoACoo]

Fortunate to work with researchers incorporating expertise across disciplines and @corp_UNC @UNCSON who are asking important questions about quality of life for older adults with AML. @danielrich21 @ChrisJensenMD @LeakBryantPhD

[Chris Jensen @ChrisJensenMD]

Our article has been included in Elsevier’s Multiple Myeloma Awareness Month article collection. To find the collection, visit https://t.co/j0wLESGMYB @OncologyAdvance @JGeriOnc #mmsm

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

Congrats @HiraSMian @tanyawildes for fascinating #ASH22 diagram!

Does #MMsm Tx make patients less frail (e.g., via ⬇️ pain) or more frail (e.g., neuropathy limiting ADLs)?

Answer - both!! But way more patients became less frail than I’d have guessed, which is great!

[Chris Jensen @ChrisJensenMD]

Thanks to @Matt_LeBlancRN for presenting our group's work in #GeriHeme #MMSM at #ASHS22 re: impact of disability on treatment outcomes for older adults with myeloma. @UNC_Lineberger @LundJenny https://t.co/yGYikXLI2p

[Chris Jensen @ChrisJensenMD]

@FernandoDiazMD1 @myCARG @UNC_Lineberger @UNCGeriatrics @DrHymanMuss @DrJaredWeiss We should definitely do this.

[The ASCO Post @ASCOPost]

Joannie M. Ivory, MD, MSPH, on Increasing Participation of Black Patients With Cancer in Clinical Trials https://t.co/pr0yfUdYP9 #ASCOQLTY22 #cancer #clinicaltrials #healthequity @UNC_Lineberger @drivorymd

[The ASCO Post @ASCOPost]

Christopher E. Jensen, MD, on Older Adults With AML: A Price Paid for High-Intensity Chemotherapy? https://t.co/uOTP0bu9Qi #leusm #leukemia #hematology #gerionc @UNC_Lineberger @ChrisJensenMD

[Chris Jensen @ChrisJensenMD]

Great work re: recruitment of Black adults to cancer trials by @drivorymd at #ASCOQLTY22. @UNC_Lineberger @StephWheelerUNC https://t.co/UViYGzBZgv

[Lorinda A. Coombs, PhD, FNP-BC, AOCNP @LoACoo]

Terence Muhammed highlight the systemic nature of health disparities, "it's not the individual fish" Highlight the good work of Racial Equity Institute in Greensboro.
#ASCOQLTY22 #RacialEquity

[Chris Jensen @ChrisJensenMD]

Excited to present at #ASCOQLTY22: Time at Home among older AML patients.
Results:
1. Treatment burden is very high
2. Pts tx w/Intensive Induction lived longer, but most time was spent engaged in care
https://t.co/zmPyAkhE8r

[Conquer Cancer, the ASCO Foundation @ConquerCancerFd]

...@JacquelyneGMD, @UlyssesG_MD, @fantinegiap, @DivyaGuptaMD, Bradley Harrison, MD, Xiao Hu, MD, MPH, @QasimHussainiMD, @ChrisJensenMD, @CharlesJiangMD, Deepika Kumar, MD, @KelseyLauMin, @Lichtenstein_MD, Francisco Martinez, MD, MS, Stephanie Ossowski, MD, MPH, Koosha Paydary, MD

[UNC Kidney Center @UNCKidney]

🚨🚨 Pub Alert 🚨🚨

Check out this collaboration from @HladikJerry & @koyaljainMD with colleagues from UNC Hem/Onc, @UNCCardiology and @UNCneurology on supporting patients with amyloidosis, an incredibly difficult disease.

@stuchman1 @mir1314

https://t.co/fYNCuCofTe